Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CLINICAL EFFICACY OF INHIBITION OF ORGAN DYSFUNCTION THROUGH BERMEKIMAB IN SYSTEMIC SCLEROSIS: A PROOF-OF-CONCEPT DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL (THE LIGHT TRIAL)

Next Previous
Trial Profile

CLINICAL EFFICACY OF INHIBITION OF ORGAN DYSFUNCTION THROUGH BERMEKIMAB IN SYSTEMIC SCLEROSIS: A PROOF-OF-CONCEPT DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL (THE LIGHT TRIAL)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bermekimab (Primary)
  • Indications Systemic scleroderma
  • Focus Proof of concept; Therapeutic Use
  • Acronyms LIGHT

Most Recent Events

  • 28 Sep 2022 Status changed from active, no longer recruiting to completed.
  • 08 Jan 2021 Status changed from recruiting to active, no longer recruiting.
  • 02 Oct 2019 According to a XBiotech media release, Evangelos Giamarellos-Bourboulis, MD, PhD, Professor of Internal Medicine, Attikon University Hospital is the principle investigator for this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top